331 Nitish et al.

Int. J. Biosci. 2020

REVIEW PAPER OPEN ACCESS

Nanocrystals: A review

B. Nitish, K. Pavithra, Singam Malathi, Khilifa Fathelrahman Khalifa Abdelmagid, S.

Jeganath*

Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science,

Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, India

Key words: Clinical trials, Nanocrystals, Nanomedicine, Nanoparticles, Nanotherapeutics, Translational

medicine.

http://dx.doi.org/10.12692/ijb/16.4.331-344 Article published on April 29, 2020

Abstract

Nanotechnology in many relevant fields, like medicine and pharmacy, can impact our lives enormously over the

next decade. Transfer of substances into the nano dimension improves their physical characteristics that have

been used in pharmaceutics to create a new revolutionary formulating method for poorly soluble drugs:

nanocrystals for medicines. The nanocrystals of drugs are not part of the future; the first drugs are still in the

marketplace. Commercially applicable processing techniques, pearl milling, and homogenization by high

pressure are checked. This addresses the mechanics behind the product nanocrystals and improvements in their

physical properties. Poorly soluble small molecules usually pose translational obstacles due to their poor

solubility, poor bioavailability and difficulties in formulating. Nano crystallization is a flexible process with the

added advantage of a provider-free delivery method to save poorly soluble drugs. We include a thorough

overview of nanocrystals in this study, including a focus on their clinical interpretation. The study also shines a

light on medically authorized nanocrystal medicinal items including those under production.

* Corresponding Author: S. Jeganath jeganaths@gmail.com

International Journal of Biosciences | IJB |

ISSN: 2220-6655 (Print), 2222-5234 (Online)

http://www.innspub.net

Vol. 16, No. 4, p. 331-344, 2020

332 Nitish et al.

Int. J. Biosci. 2020

Introduction

Nanotechnology currently is found all over our

everyday lives. If it's in microprocessor development

(in which a need to incorporate multiple

microprocessors per square millimeter is obvious to

generate more computing-powered chips) (Kanellos

M. et al., 2005). The the field of biotech (in which

new techniques are required to communicate

efficiently with proteins of ever decreasing sizes

(Merkle RC et al., 199), or literally cosmetics science

and products (where nanonized substances could

provide a wide spectrum of benefits (Müller RH et al.,

2006). This need for ever decreasing volume is

normal in these areas. A vital aspect is the

nanonization of products, either for surgical use (e.g.,

mini robots) to clear arteries (Kazimierski P et al.,

2005) and in a pharmaceutical industry (e.g.,

nanoencapsulated vitamins of organic foods, or the

use of medicinal drugs (Velikov K et al., 2006) both

economically and pharmaceutically. Since the very

first writing-through paper (in Microencapsulated ink

was used as a thin film on both the back of the top

sheet and the typewriter force removed the caps to

pass the fluid to the bottom sheet (Cinzia De Vita VC

et al., 2004). Nanotechnology has contributed to

making advances surrounding. In medical application

this review may concentrate on nanosized crystals.

The ability to nanonize (i.e. to minimize the volume to

under 1000 nm) is among the primary factors for

current drug therapy in drug delivery and medical

implementations, now and into the future years.

The amount of poorly soluble drugs has already been

gradually rising over the last ten years. Estimates

suggest that 40 per cent of pipeline products had

issues with solubility (Speiser PP et al., 1998).

Development in high-performance detection

techniques contributes to a wider range of previously

unknown medicines that are poorly soluble in water.

Theology notes which approximately 60 per cent of all

medicines that come straight from metabolism are

actually poorly soluble (Merisko-Liversidge E et al.,

2002). Low water-solubility coincides with low

bioavailability.Unless there is no way of boosting drug

solubility it won't even be able to be consumed in to

the blood circulation from the digestive tract to enter

the building of action.

Many poorly soluble medications can be solubilized in

several ways. Yet such approaches are restricted to

medicines with these kind of characteristics in terms

of their composition r, for example, their molecular

size or conformation (Grau MJ et al., 2000). In

addition, the use of surfactants or cosolvents is

technically possible, but also leads to improved

harmful effects (e.g., Cremophor EL (BASF,

Ludwigshafen, Germany) and increases the

susceptibility of Taxol and HP-β-cyclodextrin causes

itraconazole nephrotoxicity in Sporanox ® (Willems

L et al., 2001) as well as other drawbacks (e.g. organic

solvent residues). To raise the contact area and

therefore the speed of degradation, micronization of

pharmaceutical powders to sizes between 1 and 10 μm

is also not necessary to solve the intestinal absorption

concerns of several Biopharmaceutical Design Class II

drugs that are very poorly soluble. The transition

towards micronization to nanonization was a

subsequent phase. Well before the beginning of the

90s, Elan Nanosystems (San Francisco, CA, USA) has

propagated the use of nanocrystals rather than

microcrystals for both progressing oral

bioavailability, as well as using liquid condensed

nanocrystals (nanosuspensions) for intravenous or

pulmonary medication distribution.

Nanocrystals

Drug nanocrystals were nanometer-scale crystals,

meaning crystalline nanoparticles were formed.

Controversies are taking place on the concept of a

nanoparticle, meaning the size of a particle to be

defined as a nanoparticle depending on a specialty,

e.g. samples of fluid science are sometimes labeled as

nanoparticles as they are smaller than 100 nm or

often smaller than 20 nm. Depending on the size of

the plant, nanoparticles in the medicine sector should

be considered as having a length of about several nm

and 1000 nm (= 1 μm); thus, microparticles are 1–

1000 μm in size.A further attribute tends to have been

that medicine nanocrystals are constructed of 100

percent content; as with polymer nanoparticles, there

333 Nitish et al.

Int. J. Biosci. 2020

is really no material to bear. Availability of drug

nanocrystals into fluid materials ends in so-called

"nanosuspensions" (as opposed to

"microsuspensions" or "macrosuspensions").

Typically the dispersed molecules have to be

protected by surfactants or polymeric stabilizers, for

instance. The dispersing factors can well be air,

aqueous solutions, or non-aqueous media (e.g., liquid

polyethylene glycol [PEG], oils).

The drug microcrystal processing to drug

nanoparticles may result in a crystalline or

undifferentiated content, especially where

precipitation is introduced, fluctuates depending on

the production technological. An amorphous powder

nanoparticle should not be called nanocrystal in the

truest sense. Throughout the years, nanoparticles

(NPs) derived from organic and inorganic compounds

have also been developed to overcome physiological

barriers and to provide medicines for a range of

indications(De Jong WH etal 2008; Bae YH et al.,

2011) Water-insoluble or hydrophobic medicines gain

financially in order to ensure optimum bioavailability

and thus sufficient efficacy (Muller RH et al., 2004).

As reported in 2015, 40 percent of drugs on the

market and 90 percent of drugs in the research

pipeline are experiencing soluble problems (Sonvico F

et al., 2005). These figures refer as a consequence of

endogenous anhydrous solutions to 40 per cent of all

possible product targets (Savjani KT et al., 2012). In

comparison, only a handful of hydrophobic medicinal

products need scientifically relevant vectors, which

may be suitable for treatments (Anselmo AC et al.,

2014).

Both for objectives of this review of the literature,

drug nanocrystals may be categorized as small, solid

particles with quite an average size < 1 μm as well as a

crystalline attribute.

The system offers an extraordinary capacity for

providing hydrophobic drugs. Its importance stems

from the fact that nanocrystals are made completely

from a 100 % drug or even the target thus eliminating

ancillary function for a carrier (Junghanns J et al.,

2008). Alternatively, to stabilize crystal dispersions,

surfactants or stabilizers are commonly used for

liquid media.

Nanocrystalline pharmaceutical processing increases

hydrophobic drug solubility leading to an

improvement in the average volume ratio and

increased nanosizing-related degradation rates. (i.e.,

dissolution rate) (Tuomela A et al., 2016). Drug

crystals are especially ideal for the recovery of

medications considered ineffective in the Class II and

IV Biopharmaceutical Classification System (BCS)

(US Department of Health and Human Services et al.,

2017).

The BCS grading system is an analytical method that

under specified conditions it assesses the

permeability and solubility. That approach splits up

their medications into two separate groups. Whereas

Class I drugs are highly soluble and highly permeable,

Class II molecules are poorly soluble and highly

permeable, Class III is highly soluble and poorly

permeable, with poor solubility and low durability of

Class IV drugs.

Nanocrystal formulations have also proven soluble in

suspensions and are often associated with dispersions

of colloidal nanocrystals (NCDs). The dispersions

provide a platform through rendering highly stable

and commercially viable products simple to scaled up

and manufacture. These criteria for propagation or

scale-up have also been extensively discussed

elsewhere (Pawar VK et al., 2014; George J et al.,

2015). The widely used propagation methods include

the use of microfluidic systems or the flexible and

customizable milling process (Wang X, 2005;

Boleininger J 2006; Van Eerdenbrugh B 2008;

Peltonen L 2010; Lu Y 2015; Malamatari M 2018.).

Via the method of implementing nanocrystals a few

hydrophobic drugs were salvaged. The medications

have already been developed and approved

successfully by the FDA to treat a range of health

conditions ranging from dental disorders to cancer

(Merisko‐Liversidge E 2011; Chen H 2011; Brough C

334 Nitish et al.

Int. J. Biosci. 2020

2013; Möschwitzer JP 2013; Gao L 2013; Kalepu S

2015; Lee BK 2015; Lu Y 2016; Miao X 2017; Peltonen

L 2018). The approved medications can be

administered through various routes, particularly

oral, dermal, and parenteral, based on the condition.

It illustrates exactly how powerful a drug system with

nanocrystal is previous to this, information on

pharmacokinetics, bio-distribution, and

pharmacokinetics for organs engaged in transmission

pathways examined utilizing nanocrystal technology

were also extensively addressed (Shegokar R 2010;

He Y, 2015; Su H 2018, Lu PS 2018, Maudens P 2018,

and Koshani R 2018). Reviews also addresses the

biodistribution process of nanocrystal drugs in blood,

skin, liver, spleen, lung, kidney, tumor, and thymus

(i.e., organs involved in inspection / liquidity, and

immune responses) (Lu Y 2017). Several articles are

already being published explaining the techniques

utilized solely for the processing of nanocrystal

medicinal products; the type of stabilizers or

surfactants concerned; and the lessons learned about

them (Möschwitzer JP et al., 2013; Mura S et al.,

2013).There is a wide translational difference

between another hugely exciting device and its

medical recognition. In the study, we discuss the

pharmaceutical nanocrystal development from either

a translational perspective, and its development.

Given the obvious benefits of the program, people are

talking about the absence of products approved by

FDA. Discussing the challenges involved in successful

incorporation into the system.

Properties of nanocrystals

The key reasons for both higher breakdown speed

and, ultimately, increased bioavailability are: Increase

in dissolution rate by extension of surface area: The

reduction in size contributes to an enhanced total

area and therefore to a ballistic coefficient of

breakdown as per the Noyes-Whitney equation

(Noyes A, Whitney W 1897). Hence micronization is

also an effective way to effectively improve the

bioavailability of medicines in which the speed

restricting phase was the breakdown speed. The

sample layer has been further expanded by shifting

through micronization to nanonization and thus the

rate of breakup improves also. In many other

situations a higher speed of breakdown is associated

with such a higher solubility in saturated Increase in

saturation solubility: The common assumption in the

manual was that the chemical composition of

saturated cs is a constant based on the material, the

separation environment and temperature. That's true

for everyday life powders having a size in or above the

micrometer scale. Nevertheless, the concentration

viscosity often depends on both the particle size

under a crucial size of 1–2 μm. It decreases with much

less than 1000 nm of particulate matter. Chemical

nanocrystals however exhibit an improved viscosity in

saturated. It comes with couple of benefits:

First, the level of velocity is further improved as dc /

dt is proportional to the concentration of gradient

(cs−cx)/h (cs- saturation solubility, cx - bulk

concentration, h - diffusional distance).

Second, because of the enhanced permeability of

saturation, the concentration gradient among gut

lumen and blood is enhanced and thus the

penetration by passive diffusion is enhanced.

The vapor pressure of lipid droplets in such a gas

phase (aerosol) enhances through enhanced ground

thickness that implies rising particle size, as per the

Kelvin equation (Anger S 2005). Increasing fluid has

its specific substance dielectric constant, and the

liquid compression improvement would have been

determined by both the compound-specific vapor

pressure accessible. The situation of molecular

transformation from either a liquid state to a gas

phase is essentially identical to that of molecular

transition from either a solid state (nanocrystal) to a

liquid state (medium of dispersion). That intensity of

vapour is equal to the stress of destruction. There is

indeed a mixture of disintegrating substances in the

condition of saturated bioavailability, and

recrystallizing substances.

In case the breakdown stress improves and the

chemical composition of dissolution reduces, this

optimum could be changed. Within normal

335 Nitish et al.

Int. J. Biosci. 2020

circumstances (micrometer droplet size), increasing

drug crystal does have a similar micrometer-sized

dissolve stress, equivalent to fluids with similar

dielectric constant. Displays the improvement of cs

for the poorly soluble BaSO4 salt measured utilizing

Kelvin equation.

Advantages of an amorphous particle state:

Undifferentiated medicines are very well established

to have a higher solubility in concentration

comparison to crystal medicine content.

Chloramphenicol palmitate is a prime example of this

study. The polymorphic alteration I has a solubility of

0.13, the high-energy modification II does have a

viscosity of 0.43 and the amorphous substance has a

solubility of 1.6 mg / ml (Hancock BC et al., 2000;

Chong-Hui G et al., 2001).

This applies to nanoparticles used in medicines.

Undifferentiated drug nanoparticles have greater

solubility in saturated similar to crystal-state

medicine nanocrystals of similar duration. Hence a

mixture of nanometer size or undifferentiated phase

is suitable for reaching the highest concentration

soluble improvement.

Moreover, a condition to be used in pharmaceuticals

would be that the undifferentiated condition could be

preserved for both the consumer's lifespan. Passing so

many information to medicine nanocrystals indicates

which ideal medicine nanoparticles with both the

maximum improvement in penetration viscosity

ought to be e.g. 50 nm or 20–30 nm, and amorphous.

Of necessity, it should be taken into account that

blood makeup is expected with some kind of medicine

In several situations it is not preferred to dissolve too

quickly (development of large plasma peaks, decrease

of t max).

There's a need to incorporate product nanocrystals

with conventional sustained release technologies

(e.g., coated pellets) for several purposes to prevent

rapid degradation, exceptionally high plasma

increases and excessive t-max, and also to achieve

sustained plasma rates. To summarize, the ideal

nanocrystal volume and crystal / undifferentiated

condition of both the medicine would depending on:

Blood profile needed.

Route to administration.

Stability of the amorphous state during product shelf-

life.

The level should be as small as possible in the

situation of IV-nanocrystals, should the binding

affinities of a substance be reproduced. Unless the

purpose would be to (e.g., the brain using Path Finder

TM technology (Müller RH et al., 1998) or any other

organs / tissues), their drug nanocrystals ought to

have the volume to postpone the degradation and

provide them with an opportunity to reach its blood-

brain barrier (BBB) towards BBB target endothelial

body cells or some other target (Kreuter J et al.,

1995).

Production of nanocrystals

Nanocrystals can be generated in various ways in the

desired shape and size. In general, three concepts can

be used: milling, methods of precipitation and

methods of homogenisation, and also a variation

both. Topdown techniques are the industrially

applicable approaches, i.e. beginning from a huge-

sized medicine product to be scaled down. Bottom up

innovations (i.e., beginning from a dispersed

molecule, precipitation) are not presently used for the

manufacture of consumer goods, to our

understanding. Justifications can include the desire

to actually extract solvents, the challenge in managing

the system, and the reality that so many poorly

soluble drugs are not only poorly soluble in aqueous

but organic media as well.

Precipation method: Among the first measures of

precipitation is the hydrosol formulation that Sucker

created, with both the intellectual property owned by

Sandoz (Gassmann Pet al 1994; List MA, Sucker H

1988). The technique is essentially a method of

traditional precipitation, recognized as "via humida

paratum" (VHP). The VHP. The method for the

preparation of ointments including fine distributed,

336 Nitish et al.

Int. J. Biosci. 2020

catalyzed medicines was defined in the old

pharmacopeia. Nevertheless, the product needs to be

dismantled in at least one solvent which causes

problems in both aqueous and organic media for new,

insoluble, creative drugs. There are a few

explanations that this innovation have not yet been

implemented to a material, to our understanding.

Further process of precipitation is the processing of

undifferentiated medicinal nanoparticles like

carotene nanoparticles in the food industry

(Shackleford DM et al., 2003) eg, Lucarotin ® or

Lucantin ® (BASF). At a given temperature, a

carotenoid solution and a surfactant in a digestible oil

are combined with a suitable solvent.A safe colloid is

applied to arrive at the solution. That results in a two-

phase O / W system. In the oily process, the colloid-

stabilized carotenoid localizes. X-ray analyzes after

lyophilization reveal that about 90 per cent of the

carotenoid is in an amorphous state. Soliqs uses this

technique for pharmaceuticals, and advertises it

underneath the trade name NanoMorph ®.

Milling method: Standard NanoCrystals ® method

uses a beads or a pear mill to accomplish reduction in

particle size. Ball mills have already been recognized

for both the development of ultrafine suspensions

from the very first half of the 20th century (Pahl

MH. Zerkleinerungstechnik. Cologne 1991). In the

machining chamber are loaded milling plates,

diffusion medium (usually water), stabilization, and

product. Impact shear forces, created by the motion

of the machining media, result in reducing of the

particle size. Unlike higher pressure homogenisation,

it is a method of small-energy-milling. The balls are

composed of resin-coated polystyrene beads made

from ceramics, stainless steel, and glass or closely

interlaced. A significant problem of this engineering

is the erosion from either the friction content during

most of the milling method. The friction particles are

treated to minimize the amount of contaminants

induced by both the degradation of the milling media

(Bruno JA et al., 1992). A further issue is the new

product compliance to the mill's inner surface (which

consists primarily of both the milling pearl surface

and the mill surface as a whole).Friction would have

two main principles. If the turbulence press is pushed

through such an agitator or even the whole tank is

pushed in a fluid motion that contributes to the

turbulence press revolution (Merisko-Liversidge E et

al., 2003). This approach is an interesting technology

of reducing particle volume that is illustrated through

the use of four FDA-approved drugs which could later

be the subject of this document.

Homogenization method: There are three main

developments in the production of nanocrystals using

homogenization techniques: microfluidizer

technology (IDD-PTMTM engineering), water piston

gap homogenization (Dissocubes ® innovation).

Microfluidizers are designed to create small particles

under stress of up to 1700 bar (Bruno RP et al 1999)

by a simple head on collision of two fluid fluxes. It

leads to particle collision, to tensile forces and to

cavitation forces (Tunick MH et al., 2002). Jet stream

homogenizers including the micro fluidizer

(Microfluidizer ®, Microfluidics Inc.) can achieve it.

That cavity for both the collision could be developed

in two versions, whether Y-type or Z-type.

Fortunately, for a reasonable reduction in particle

size, a relatively significant amount of loops (50 to

100 passes) is required. With its Insoluble Drug

Discovery (IDD) technology, SkyePharma uses this

principle to accomplish poorly soluble growth of

submicron particulate matter. For addition, the

Dissocubes ® method requires piston range

homogenizers. SkyePharma PLC discovered a route,

and bought it later(Müller RH et al., 1995 and Müller

RH et al 1999).It is processing suspensions of

nanoparticles in liquid at room temperature. A

product substance is spread in an aqueous surfactant

mixture and then pushed by both a piston through the

narrow homogenization gap through forces of up to

4000 bar, usually between 1500 and 2000 bar. The

length of the homogenization gap ranges from around

(Möschwitzer J 2005) 5 to 20 μm, fluctuates

depending from both the viscosity of both the

suspension as well as the pressure becoming

introduced. The resulting high tension transmission

337 Nitish et al.

Int. J. Biosci. 2020

velocity causes an increase in kinetic pressure, which

would be compensated by a decline in dynamic

pressure there under aqueous dielectric constant of

the system (as per Bernoulli's law).

Gas bubbles form when the water starts to boil at

room temperature. These gas bubbles spontaneously

burst as the liquid exits the homogenisation gap

during normal air stress of 1 bar again.

This occurrence of gas bubble formation and

implosion is called vortex shedding which leads to

concussive blasts. Due to the strong shear forces,

vigorous flow and the immense strength of these

shockwaves, the product fragments are diminished in

size (Muller RH 2001). Of course water usage may

have drawbacks, e.g. hydrolysis of liquid-sensitive

medicines and issues throughout corresponding

drying steps (such as removing too much

water).Hence the technique is ideally suited for

formulating aqueous nanocrystal suspensions (Muller

RH 2003).

The Nanopure ® process, operated and established

by PharmaSol GmbH in Berlin, is yet another

technique that uses the piston-gap homogeniser. The

method requires low vapor pressure dispersion

media, and likely homogenisation at low

temperatures. The cavitation within the

homogenisation distance is rather small or zero. The

size decrease was acceptable even without

deformation (Bushrab NF et al., 2003). Nanoparticles

involve the residual frictional forces, collisions with

particles, and turbulences. The low temperatures

necessary for manufacturing heat labile drugs when

homogenizing (Müller RH et al., 2002). For quasi-

aqueous conditions, essentially the entire process

should also be conducted to protect medicines

towards hydrolysis. They can be packed immediately

into gelatin or HPMC capsules using oils, PEG or hot-

melted polyethylene glycols (Keck CM 2004).

Only the accompanying approaches are present in

order to provide a full description of accessible

technology. The organization Baxter uses a

precipitation stage for its NanoEdgeTM technology by

introducing high energy, e.g., highshear and/or

thermal energy (Kipp JE et al., 2003) with

corresponding annealing phase. PharmaSol uses a

pretreatment step with corresponding

homogenisation in its Nanopure XP technology to

generate particles far below 100 nm (Müller RH 1996;

Müller RH 2005; Lee S 2005).

Nanocrystal drug product

Nanocrystals has been a subject of high technology

development activity because of our high property

charging performance, consistent breakdown levels,

improved structural strength and extended diffusion

periods. Many drugs are still on the marketplace, and

human trials are also under way for a range of other

products.

Nanocrystal‐drug products in the market: Through

1995, the FDA has authorized ~50 nanodrugs for

different applications, mainly centered on liposomes,

polymers, and nanocrystals (Bobo D 2016; Caster JM

2017). Nanocrystallization is an efficient means of

formulating and producing poorly soluble drugs. The

technology's market appeal will be further boosted by

the relatively short period period towards clinical

acceptance. Although liposomes took approximately

25 years to commercialize, Emend ®'s relative

graphical fidelity was just 10 years. The first patent

application for Emend was submitted in 1990, and

the company was released in 2000. Thus, a

considerable number of nanocrystal drug products

were established and successfully tested within the

same short time, relative to other nanosized

frameworks.

A first branded nanocrystal drug medicine, launched

by Wyeth Pharmaceutical products in 2000, was

Rapamune ®, a poorly soluble immunosuppressant

Sirolimus (SRL). Rapamune was manufactured and

use the process of pearl milling and its binding

affinity in its traditional oral solution formulation was

observed to be 21 per cent higher than SRL. These

were followed by the creation in 2003 of Emend

(Aprepitant), by Merck. Emend was formed from

338 Nitish et al.

Int. J. Biosci. 2020

Aprepitant — a moderately water-soluble pro-emetic

drug that can be consumed only in the upper

gastrointestinal tract and has a small absorption

period.Tricor ®, which was introduced by Abbott

Laboratories in 2003, was developed and use the

pearl mill manufacturing method from fenofibrate— a

lipophilic drug for hypercholestremia. Formulating

fenofibrate into nanocrystals strengthened its

insulative properties to both the gut wall and

enhanced its binding affinity by 9 percent regardless

of whether it is fed or fasted. It has given way for

patients to provide a simpler, adjustable sublingual

routine. The nanocrystal drug product inspired by

fenofibrate is Triglide ®, which Skyepharma had

launched in 2005.

Megace ES was made from megestrol acetate into

nanocrystals–a consuming painkiller utilizing pearl

milling technique. This improved its degradation

frequency and decreased the single dose size by

several times, thereby improving its binding affinity

and user adherence with extremely aggressive

megestrol acetate as compared to oral suspension.

Nanocrystal drug‐products in clinical trials: Most

nanocrystal medicinal properties are currently

recommended for oral consumption and treatment of

besides cancer diseases. The oral management market

is large and, relative to injectables, the road to

marketing is smoother. The process of product

approval for nanocrystal product substances is easier

as the content consists primarily of the

pharmaceutical which can be mixed with GRAS-

approved stabilisers and inert ingredients. Although

there has currently been several nanocrystal drugs in

clinical trials taking into consideration the feasibility

of accelerated development and marketing. Cytokine

Pharamsciences (CPSI) Semapimod ® nanocrystals is

a synthetic guanylhydrazone and has already been

observed to function as just an immunomodulator,

preventing the development of TNF‐α, a

proinflammatory cytokine that is involved in

inflammatory reaction-in cancer patients throughout

a Phase I study(Home ‐ Ferring Corporate

2018). After only a comprehensive clinical trial, CPSI

also found that the drug has been effective in

preventing psoriasis and Crohn's disease mild to

extreme. The nanocrystal drug commonly used

during clinical studies is PAXCEEDTM from

Angiotech Pharmaceutical products, In.(Raghava

Srivalli KM, Mishra B. 2016).PAXCEED is made of

paclitaxel and is a medicinal drug free of EL

cremophorus. This might greatly minimize

oversensitivity in patients diagnosed with cancer or

with chronic inflammation. Celmed BioSciences Inc.

(Saint-Laurent, QC)'s TheraluxTM is a photodynamic

counseling-based thymectacin management tool that

is poorly soluble and poor bioavailability (New Biotic.

2018). Inflammatory disorders, anti-Hodgkin's

lymphoma, bowel cancer and the prevention of graft-

versus-host infection are presently under evaluation.

Nucryst Pharmaceuticals (Wakefield, MA) established

a cream composition centered on a patented NPI

32101 material that mainly consists of silver

nanocrystals (Bhol KC 2004; Bhol KC 2005). The

medicine exhibited encouraging antifungal and non-

inflammatory properties (Lyczak J 2005). Phase II

clinical trials for atopic dermatitis are due to be

completed at NPI 32101. Panzem ® NCDs is

developed out of 2‐Methoxyestradiol (2‐ME2)—a

legitimate estradiol metabolite (EntreMed, Inc.). In

preclinical trials, 2‐ME2 displayed encouraging

antiproliferative and antiangiogenic attributes.

Entremed then went on with Panzem to assess her

operation toward ovarian cancer, and other strong

carcinomas. It could not go through Phase II

nevertheless, and then all of Panzem's clinical growth

was suspended (Harrison MR 2011).

Conclusion

As the descriptions has demonstrated, only with a

certain slight disadvantages, nanocrystal company

provides enormous benefits. This is specifically best

suited for medications that have issues with

solubility. Diminishment of particle size and the

resulting increase in particle density, thickness,

bioavailability in aggregation, and therefore the

enhanced velocity of dissolution, are important

factors. Improving bioavailability alone isn't the only

critical factor. Whenever a medicine has a small

339 Nitish et al.

Int. J. Biosci. 2020

functional period where it could be consumed it is

much more essential. The improved solubility and

speed When a wide dosage is needed to maintain

acceptable levels in the blood for poorly soluble drugs

leading to greater side effects, the nanocrystal

technology enables for smaller doses and decreased

adverse effects as an implication. The drawbacks are

the processing periods that are often long, e.g. in

pearl milling. Nevertheless, new inventions have only

been submitted to automate wide scale development,

e.g., H42. Additionally, there is a need for modern

technologies to manufacture tablets containing high

medicine nanocrystal volumes to manufacture high-

dose medicines in–preferentially–one single tablet..

For both the nanoparticles it will be an essential part

of the research in particular

References

Anger S. 2005. Pharmazeutische Technologie.

Berlin, Freie Universität; PhD Thesis.

Anselmo AC, Mitragotri S. 2014. An overview of

clinical and commercial impact of drug delivery

systems. Journal of Control Release 190, 15‐28.

http://dx.doi.org/10.1016/j.jconrel.2014.03.053

Bae YH, Park K. 2011. Targeted drug delivery to

tumors: myths, reality and possibility. Journal of

Control Release153, 198‐205.

http://dx.doi.org/10.1016/j.jconrel.2011.06.001

Bhol KC, Alroy J, Schechter PJ.

2004. Anti‐inflammatory effect of topical

nanocrystalline silver cream on allergic contact

dermatitis in a Guinea pig model. Clinical and

Experimental Dermatology 29, 282‐287.

http://dx.doi.org/10.1111/j.1365- 2230.2004.01515.x

Bhol KC, Schechter PJ. 2005. Topical

nanocrystalline silver cream inhibits expression of

matrix metalloproteinase‐9 in animal models of

allergic contact dermatitis. The British Journal of

Dermatology 152(6), 1235-42.

http://dx.doi.org/10.1111/j.1365-2133.2005.06575.x

Bobo D, Robinson KJ, Islam J, Thurecht KJ,

Corrie SR. 2016. Nanoparticle‐based medicines: a

review of FDA‐approved materials and clinical trials

to date. Pharmaceutical Research 33, 2373‐2387.

http://dx.doi.org/10.1007/s11095-016-1958-5

Boleininger J, Kurz A, Reuss V, Sönnichsen C.

2006. Microfluidic continuous flow synthesis of

rod‐shaped gold and silver nanocrystals. Physical

Chemistry Chemical Physics 8, 3824‐3827.

https://doi.org/10.1039/B604666E

Brough C, Williams RO. 2013. Amorphous solid

dispersions and nano‐crystal technologies for poorly

water‐soluble drug delivery. International Journal of

Pharmaceutics 453, 157‐166.

http://dx.doi.org/10.1016/j.ijpharm.2013.05.061

Bruno JA, Doty BD, Gustow E. 1992. Method of

grinding pharmaceutical substances. US Patent

5518187; USA.

Bruno RP, McIlwrick R. 1999. Microfluidizer

processor technology for high performance particle

size reduction, mixing and dispersion. European

Journal of Pharmaceutics and Biopharmaceutics 56,

29–36.

Bushrab NF, Müller RH. 2003. Nanocrystals of

poorly soluble drugs for oral administration. Journal

of New Drugs. 5, 20–2.

Caster JM, Patel AN, Zhang T, Wang A.

2017. Investigational nanomedicines in 2016: a

review of nanotherapeutics currently undergoing

clinical trials. wiley interdiscip rev nanomed

nanobiotechnol journal 9, e1416.

http://dx.doi.org/10.1002/wnan.1416

Chen H, Khemtong C, Yang X, Chang X, Gao J.

2011. Nanonization strategies for poorly water‐soluble

drugs. Drug Discovery Today 16, 354‐360.

http://dx.doi.org/10.1016/j.drudis.2010.02.009

Chong-Hui G, Grant DJW. 2001. Estimating the

340 Nitish et al.

Int. J. Biosci. 2020

relative stability of polymorphs and hydrates from

heats of solution and solubility data. Journal of

Pharmaceutical Sciences 909, 1277–87.

https://doi.org/10.1002/jps.1080

Cinzia De Vita VC. 2004. Nanostructured hybrid

materials from aqueous polymer

dispersions. Advances in Colloid and Interface

Science 108–109C, 167–85.

http://dx.doi.org/10.1016/j.cis.2003.10.017

De Jong WH, Borm PJA. 2008. Drug delivery and

nanoparticles: applications and hazards.

International Journal of Nanomedicine 3, 133‐149.

http://dx.doi.org/10.2147/ijn.s596

Gao L, Liu G, Ma J. 2013. Application of drug

nanocrystal technologies on oral drug delivery of

poorly soluble drugs. Pharmaceutical Research 30,

307‐324.

http://dx.doi.org/10.1007/s11095-012-0889-z

Gao L, Liu G, Ma J, Wang X, Zhou L, Li

X. 2012. Drug nanocrystals: in vivo

performances. Journal of Controlled Release 160,

418‐430.

http://dx.doi.org/10.1016/j.jconrel.2012.03.013

Gassmann P, List M, Schweitzer A. 1994.

Hydrosols – alternatives for the parenteral

application of poorly water-soluble drugs. European

Journal of Pharmaceutics and Biopharmaceutics 40,

64–72.

George J, Sabapathi SN. 2015. Cellulose

nanocrystals: synthesis, functional properties, and

applications. Nanotechnology, Science and

Applications 8, 45‐54

http://dx.doi.org/10.2147/NSA.S64386.

Grau MJ. Dissertation. Pharmazeutische

Technologie. Berlin: Freie Universität; 2000.

Untersuchungen zur Lösungsgeschwindigkeit,

Sättigungslöslichkeit und Stabilität von

hochdispersen Arzneistoffsuspensionen.

Hancock BC, Parks M. 2000. What is the true

solubility advantage for amorphous

pharmaceuticals? Pharmaceutical Research 174,

397–404

http://dx.doi.org/10.1023/a:1007516718.048

Harrison MR, Hahn NM, Pili R. 2011. A phase II

study of 2‐methoxyestradiol (2ME2) NanoCrystal®

dispersion (NCD) in patients with taxane‐refractory,

metastatic castrate‐resistant prostate cancer

(CRPC). Investigational New Drugs 29, 1465‐1474.

http://dx.doi.org/10.1007/s10637-010-9455-x

He Y, Xia DN, Li QX, Tao JS, Gan Y, Wang

C. 2015. Enhancement of cellular uptake, transport

and oral absorption of protease inhibitor saquinavir

by nanocrystal formulation. Acta Pharmacologia

Sinica 36, 1151‐1160

http://dx.doi.org/10.1038/aps.2015.53.

Junghanns J, Müller R. 2008. Nanocrystal

technology, drug delivery and clinical

applications. International Journal of

Nanomedicine 3(3), 295‐309.

Kalepu S, Nekkanti V. 2015. Insoluble drug

delivery strategies: review of recent advances and

business prospects. Acta Pharma Sinica B 5, 442‐453.

https://doi.org/10.1016/j.apsb.2015.07.003

Kanellos M. Moore says nanoelectronics face tough

challenges. CNet News. 2005. [online]. 9 March. url

Kazimierski P, Alexander. Von Humboldt

Foundation Conference 2005. Piotr: Alexander von

Humboldt Foundation; Nanotechnology for medicine.

Keck CM, Bushrab NF, Müller RH. Nanopure®

nanocrystals for oral delivery of poorly soluble drugs.

Particles; April 20–23, 2002; Orlando, Florida, USA.

2004.

Kipp JE, Wong JCT, Doty MJ, Microprecipitation

method for preparing submicron suspensions. US

Patent 6607784; USA: 2003.

341 Nitish et al.

Int. J. Biosci. 2020

Koshani R, Madadlou AA 2018. Viewpoint on the

gastrointestinal fate of cellulose nanocrystals. Trends

in Food Science & Technology 71, 268‐273.

https://doi.org/10.1016/j.tifs.2017.10.023

Kreuter J, Alyautdin RN, Kharkevich DA. 1995.

Passage of peptides through the blood – brain barrier

with colloidal polymer particles nanoparticles. Brain

Research 674(1), 171–4.

http://dx.doi.org/10.1016/0006-8993(95)00023-j

Lee BK, Yun YH, Park K. 2015. Smart

nanoparticles for drug delivery: boundaries and

opportunities. Chemistry of Engineering and Science

125, 158‐164.

http://dx.doi.org/10.1016/j.ces.2014.06.042

Lee S, Nam K, Kim MS. 2005. Preparation and

characterization of solid dispersions of itraconazole

by using aerosol solvent extraction system for

improvement in drug solubility and

bioavailability. Archieves of Pharmacia Research 287,

866–74.

List MA, Sucker H. Pat No. GB 2200048. Great

Britian: 1988.

Lu PS, Inbaraj BS, Chen BH. 2018.

Determination of oral bioavailability of curcuminoid

dispersions and nanoemulsions prepared

from Curcuma longa Linnaeus. Journal of the Science

of Food and Agriculture 98, 51‐63.

http://dx.doi.org/10.1002/jsfa.8437

Lu Y, Chen Y, Gemeinhart RA, Wu W, Li

T. 2015. Developing nanocrystals for cancer

treatment. Nanomedicine. 10, 2537‐2552.

http://dx.doi.org/10.1002/jsfa.8437

Lu Y, Li Y, Wu W. 2016. Injected nanocrystals for

targeted drug delivery. Acta Pharma Sinica B 6,

106‐113.

http://dx.doi.org/10.1016/j.apsb.2015.11.005

Lu Y, Qi J, Dong X, Zhao W, Wu W. 2017. The in

vivo fate of nanocrystals. Drug Discovery Today 22,

744‐750.

http://dx.doi.org/10.1016/j.drudis.2017.01.003

Lyczak J, Schechter P. 2005. Nanocrystalline

silver inhibits antibiotic‐, antiseptic‐resistant

bacteria. American Society for Clinical Pharmacology

and Therapeutics 77, P60‐P60.

https://doi.org/10.1016/j.clpt.2004.12.119

Malamatari M. 2018. Pharmaceutical nanocrystals:

production by wet milling and applications. Drug

Discovery Today. 23, 534‐547.

http://dx.doi.org/10.1016/J.DRUDIS. 2018. 01.016.

Maudens P, Seemayer CA, Thauvin C, Gabay

C, Jordan O, Allémann E. 2018.

Nanocrystal‐polymer particles: extended delivery

carriers for osteoarthritis treatment. Small 14.

http://dx.doi.org/170310810.1002/smll.201703108.

Merisko-Liversidge E, Liversidge GG, Copper

ER. 2003. Nanosizing: a formulation approach for

poorly-water-soluble compounds. European Journal

of Pharmaceutical Sciences 18, 113–20.

http://dx.doi.org/10.1016/s0928-0987(02)00251-8

Merisko‐Liversidge E, Liversidge GG. 2011.

Nanosizing for oral and parenteral drug delivery: a

perspective on formulating poorly‐water soluble

compounds using wet media milling

technology. Advanced Drug Delivery Reviews 63,

427‐440.

http://dx.doi.org/10.1016/j.addr.2010.12.007

Merisko-Liversidge E. 2002. Nanocrystals:

Resolving pharmaceutical formulation issues

associated with poorly water-soluble compounds.

Particles; April 20–23, Orlando, Florida, USA.

Merkle RC. 1999. Biotechnology as a route to

nanotechnology. Trends in Biotechnology 17, 271-4

http://dx.doi.org/10.1016/s0167-7799(99)01335-9

Miao X, Yang W, Feng T, Lin J, Huang P. 2017.

342 Nitish et al.

Int. J. Biosci. 2020

Drug nanocrystals for cancer therapy. Wiley

Interdisciplinary Reviews Nanomedicine and Nano

biotechnology 10, e1499

http://dx.doi.org/10.1002/wnan.1499.

Möschwitzer J. Pharmazeutische

Technologie. Freie Universität; Berlin: 2005. PhD

Thesis (in preparation)

Möschwitzer JP, Müller RH. 2013. Factors

influencing the release kinetics of drug

nanocrystal‐loaded pellet formulations. Drug

Development and Industrial Pharmacy 39, 762‐769.

https://doi.org/10.3109/03639045.2012.702347

Möschwitzer JP. 2013. Drug nanocrystals in the

commercial pharmaceutical development

process. International Journal of Pharmaceutics 453,

142‐156.

http://dx.doi.org/10.1016/j.ijpharm.2012.09.034

Müller BW, Bleich J. 1996. Production of drug

loaded microparticles by the use of supercritical gases

with the Aerosol Solvent Extraction System (ASES)

process. Journal of Microencapsulation 132, 131–9.

http://dx.doi.org/10.3109/0265204960 9052902

Müller RH, Becker R, Kruss B.

1999.Pharmaceutical nanosuspensions for

medicament administration as systems with

increased saturation solubility and rate of

solution. US Patent 5858410; USA:

Müller RH, Jacobs C, Kayser O. 2003.

DissoCubes – a novel formulation for poorly soluble

and poorly bioavailable drugs. In: Rathbone MJ,

Hadgraft J, Roberts MS, editors. Modified-release

drug delivery systems. New York: Marcel Dekker; p.

135–49.

Muller RH, Jacobs C, Kayser O. 2001.

Nanosuspensions as particulate drug formulations in

therapy: Rationale for development and what we can

expect for the future. Advanced Drug Delivery

Reviews. 471, 3–19.

http://dx.doi.org/10.1016/s0169-409x(00)00118-6

Muller RH, Keck CM. 2004. Challenges and

solutions for the delivery of biotech drugs – a review

of drug nanocrystal technology and lipid

nanoparticles. Journal pf Biotechnology 113, 151‐170.

http://dx.doi.org/10.1016/j.jbiotec.2004.06.007

Müller RH, Lück M, Kreuter

J. Arzneistofträgerpartikel für die gewebsspezifische

Arzneistoffapplikation. Germany: 1998.

PCT/EP98/06429.

Müller RH, Möschwitzer JP. 2005. Method and

apparatus for the production of ultrafine particles and

coating of such particles. German 53 862.2

Application.

Müller RH, Pardeike J, Hommoss A.

Nanoparticles in therapeutics: drug nanocrystals and

lipid nanoparticles. MSTI-Congress NanoTrends

2006; Berlin, Germany.

Müller RH, Peters K, Becker R. 1995.

Nanosuspensions – a novel formulation for the IV

administration of poorly soluble drugs. 1st World

Meeting of the International Meeting on

Pharmaceutics, Biopharmaceutics and

Pharmaceutical Technology; Budapest.

Müller RH. 2002. Nanopure technology for the

production of drug nanocrystals and polymeric

particles. 4th World Meeting of the Italian

Association of Professors and Academic Researchers

of Pharmaceutics, Pharmaceutical Technology,

Biopharmaceutics and Regulatory Affairs; Florence,

Italy.

Mura S, Nicolas J, Couvreur P. 2013.

Stimuli‐responsive nanocarriers for drug

delivery. Nature Materials. 12, 991‐1003. New

Biotic. Accessed December 19, 2018.

https://doi.org/10.1038/nmat3776

https://www.newbiotic.com/

343 Nitish et al.

Int. J. Biosci. 2020

Noyes A, Whitney W. 1897. The rate of solution of

solid substances in their own solutions. Journal of the

American Chemical Society. 19, 930–4

http://dx.doi.org/10.1021/ja02086a003

Pahl MH. Zerkleinerungstechnik. Cologne: TÜV

Rheinland GmbH; 1991.

Pawar VK, Singh Y, Meher JG, Gupta S,

Chourasia MK. 2014 Engineered nanocrystal

technology: in‐vivo fate, targeting and applications in

drug delivery. Journal of Controlled Release 183,

51‐66.

http://dx.doi.org/10.1016/j.jconrel.2014.03.030

Peltonen L, Hirvonen J. Drug nanocrystals–

versatile option for formulation of poorly soluble

materials. International Journal of Pharmaceutics

537, 73‐83.

http://dx.doi.org/10.1016/j.ijpharm.2017.12.005

Peltonen L, Hirvonen J. 2010. Pharmaceutical

nanocrystals by nanomilling: critical process

parameters, particle fracturing and stabilization

methods. Journal of Pharmacy and Pharmacology 62,

1569‐1579.

http://dx.doi.org/10.1111/j.2042-7158. 2010.01022.x

Raghava Srivalli KM, Mioshra B. 2016. Drug

nanocrystals: A way toward scale‐up. Saudi

Pharmaceutical Journal 24(4), 386‐404.

http://dx.doi.org/10.1016/j.jsps.2014.04.007

Savjani KT, Gajjar AK, Savjani JK. 2012. Drug

solubility: importance and enhancement

techniques. ISRN Pharmacology. 012, 195727

https://doi.org/10.5402/2012/195727

Shackleford DM, Faassen WA, Houwing N.

2003. Contribution of lymphatically transported

testosterone undecanoate to the systemic exposure of

testosterone after oral administration of two andriol

formulations in conscious lymph duct-cannulated

dogs. Journal of Pharmacology and Experimental

Therapeutics 306(3), 925–33.

http://dx.doi.org/10.1124/jpet.103.052522

Shegokar R, Müller RH. 2010. Nanocrystals:

industrially feasible multifunctional formulation

technology for poorly soluble actives. International

Journal of Pharmaceutics 399, 129‐139.

http://dx.doi.org/10.1016/j.ijpharm.2010.07.044

Sonvico F, Mornet S, Vasseur S. 2005.

Folate‐conjugated iron oxide nanoparticles for solid

tumor targeting as potential specific magnetic

hyperthermia mediators: synthesis, physicochemical

characterization, and in vitro experiments.

Bioconjugate Chemistry 16, 1181‐1188.

http://dx.doi.org/10.1021/BC050050Z.

Speiser PP. 1998. Poorly soluble drugs: a challenge

in drug delivery. In: Müller RH, Benita S, Böhm B,

editors. Emulsions and nanosuspensions for the

formulation of poorly soluble drugs. Medpharm

Stuttgart: Scientific Publishers; p 15–28

Su H, Wang Y, Gu Y, Bowman L, Zhao J, Ding

M. 2018. Potential applications and human biosafety

of nanomaterials used in nanomedicine. Journal of

Applied Toxicology 38, 3‐24.

http://dx.doi.org/10.1002/jat.3476

Tunick MH, Van Hecken DL, Cooke PH, et al.

2002. Transmission electron microscopy of

mozzarella cheeses made from microfluidized

milk. Journal of Agriculture and Food Chemistry 50,

99–103.

http://dx.doi.org/10.1021/jf010633c

Tuomela A, Saarinen J, Strachan CJ,

Hirvonen J. 2016. Production, applications and in

vivo fate of drug nanocrystals. Journal of Drug

Delivery Science and Technology 34, 21‐31.

https://doi.org/10.1016/j.jddst.2016.02.006

US Department of Health and Human

Services, Food and Drug Administration

Center for Drug Evaluation and Research.

2017. Waiver of in vivo bioavailability and

344 Nitish et al.

Int. J. Biosci. 2020

bioequivalence studies for immediate‐release solid

Oral dosage forms based on a biopharmaceutics

classification system guidance for

industry. Biopharmaceutics. 1‐19.

Van Eerdenbrugh B, Van den Mooter G,

Augustijns P. 2008. Top‐down production of drug

nanocrystals: nanosuspension stabilization,

miniaturization and transformation into solid

products. International Journal of Pharmaceutics

364, 64‐75.

https://doi.org/10.1016/j.ijpharm.2008.07.023

Velikov K. Colloidal delivery systems for functional

food design. 9th Annual NSTI Nanotechnology

Conference and Trade Show, Nanotechnology 2006;

Boston, Massachusetts, USA. 2006.

Wang X, Zhuang J, Peng Q, Li Y. A 2005.

General strategy for nanocrystal synthesis. Nature

437, 121‐124

https://doi.org/10.1038/nature03968

Willems L, Van der Geest R, de Beule K. 2001.

Itraconazole oral solution and intravenous

formulations: a review of pharmacokinetics and

pharmacodynamics. Journal of Clinical therapeutics

and Pharmcy 26, 159–61

https://doi.org/10.1046/j.1365-2710.2001.00338.x